RAGE and its ligands in cancer - culprits, biomarkers, or therapeutic targets?

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10295803" target="_blank" >RIV/00216208:11110/15:10295803 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/15:10295803
Result on the web
<a href="http://dx.doi.org/10.4149/neo_2015_061" target="_blank" >http://dx.doi.org/10.4149/neo_2015_061</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.4149/neo_2015_061" target="_blank" >10.4149/neo_2015_061</a>

Result language
angličtina
Original language name
RAGE and its ligands in cancer - culprits, biomarkers, or therapeutic targets?
Original language description
Receptor for advanced glycation end products (RAGE) plays a central role in the regulation of tissue homeostasis, regeneration and resolution of inflammation, but under pathological conditions RAGE-mediated pathways may induce diminished apoptosis, but enhanced autophagy and cell necrosis. These mechanisms may contribute to malignant transformation, cancer progression and metastases. Soluble RAGE may bind natural RAGE ligands and counteract some of the RAGE-mediated effects. Activation of RAGE was demonstrated in different types of cancer (including colon, pancreatic and breast cancer). Expression of RAGE and serum levels of soluble RAGE may serve as cancer biomarkers and strategies aimed at interfering with RAGE signaling might be promising anticancerdrugs.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)